Otsuka Holdings Co (JP:4578) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Otsuka Holdings Co., Ltd. has announced the approval of an additional indication for its drug Rexulti in Japan, for treating agitation associated with Alzheimer’s disease. The approval follows successful phase 3 trials showing significant improvement in agitation symptoms, with the drug being well tolerated among patients. This marks the third indication for Rexulti in Japan, which is part of Otsuka’s commitment to addressing the needs of an aging population and providing comprehensive care options.
For further insights into JP:4578 stock, check out TipRanks’ Stock Analysis page.